Active, not recruitingPhase 2NCT05022654
SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.
Studying Squamous cell carcinoma of the esophagus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Principal Investigator
- Lin ShenPeking University Cancer Hospital & Institute
- Intervention
- SI-B001(drug)
- Enrollment
- 22 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2025
Study locations (6)
- Beijing Cancer Hostital, Beijing, Beijing Municipality, China
- Anyang Cancer Hospital of Henan Province, Anyang, Henan, China
- The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
- Xuzhou Central Hospital, Xuzhou, Jiangsu, China
- Shanxi Cancer Hospital, Taiyuan, Shanxi, China
- Suining Central Hospital, Suining, Sichuan, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05022654 on ClinicalTrials.govOther trials for Squamous cell carcinoma of the esophagus
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07457528Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCCTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE2NCT07331155A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]Nanjing Leads Biolabs Co.,Ltd
- RECRUITINGPHASE1NCT07503808A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesIDEAYA Biosciences
- RECRUITINGPHASE2NCT07403136Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCCFudan University
- RECRUITINGPHASE1, PHASE2NCT07385001A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCCTang-Du Hospital
- RECRUITINGPHASE2NCT07263919Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)Akeso
- RECRUITINGPHASE2NCT07481058KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal CancerBeijing Konruns Pharmaceutical Co., Ltd.
- RECRUITINGPHASE1NCT07217171A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell CarcinomasEvolveImmune United, Inc
See all trials for Squamous cell carcinoma of the esophagus →